Page 3 - Glp1

How 2025 marked a turning point for health science and innovation

From GLP-1 drugs and personalised cancer vaccines to longevity experiments and regenerative therapies, 2025 marked a year when scientific breakthroughs reshaped healthcare and medicine

From fibremaxxing to GLP-1s: What were India's top health trends in 2025?

From fibremaxxing and longevity clinics to GLP-1 drugs, AI hospitals and workplace mental health, 2025 reshaped how India talks about prevention, ageing and wellbeing

Emcure targets pan-India obesity market with Poviztra semaglutide

As GLP-1 competition heats up, Emcure is pricing semaglutide brand Poviztra at ₹8,790 a month and targeting demand beyond metros with deeper distribution in smaller cities

Mounjaro and the brain: Why cravings fade at first, then return later

A rare brain-recording study found tirzepatide briefly muted activity linked to 'food noise'; months later the signals and intrusive thoughts returned, hinting at limits to its effect

GLP-1 weight-loss drugs likely to see value growth slowing down

Entry of generics post March 2026, patient dropouts to affect sales values, say experts

Ozempic in India: What it does and how it fits into a growing health crisis

From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions

Novo Nordisk launches Ozempic in India at ₹2,200/week amid patent battles

Ozempic debuts in India at ₹2,200 per week, offering a new treatment option for type 2 diabetes as demand grows for effective and easy-to-use metabolic health therapies